167 related articles for article (PubMed ID: 7646929)
1. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells.
Liu XH; Blazsek I; Comisso M; Legras S; Marion S; Quittet P; Anjo A; Wang GS; Misset JL
Eur J Cancer; 1995 Jun; 31A(6):953-63. PubMed ID: 7646929
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.
Yi SN; Wass J; Vincent P; Iland H
Leuk Res; 1991; 15(10):883-6. PubMed ID: 1921448
[TBL] [Abstract][Full Text] [Related]
3. Effect of norcantharidin on the human breast cancer Bcap-37 cells.
Liu D; Shi P; Yin X; Chen Z; Zhang X
Connect Tissue Res; 2012; 53(6):508-12. PubMed ID: 22606958
[TBL] [Abstract][Full Text] [Related]
4. Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production.
Liao HF; Chen YJ; Chou CH; Wang FW; Kuo CD
Toxicol In Vitro; 2011 Feb; 25(1):206-12. PubMed ID: 21075198
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
6. The preliminary observation on immunosuppressive effect of norcantharidin in mice.
Yan MS; Xiue S; Wei LX; Piao XH
Immunopharmacol Immunotoxicol; 1993 Jan; 15(1):79-85. PubMed ID: 8450182
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.
Kok SH; Hong CY; Kuo MY; Lee CH; Lee JJ; Lou IU; Lee MS; Hsiao M; Lin SK
Oral Oncol; 2003 Jan; 39(1):19-26. PubMed ID: 12457717
[TBL] [Abstract][Full Text] [Related]
8. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells.
Chen YJ; Kuo CD; Tsai YM; Yu CC; Wang GS; Liao HF
Anticancer Drugs; 2008 Jan; 19(1):55-64. PubMed ID: 18043130
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells.
Liao HF; Su SL; Chen YJ; Chou CH; Kuo CD
Food Chem Toxicol; 2007 Sep; 45(9):1678-87. PubMed ID: 17442474
[TBL] [Abstract][Full Text] [Related]
10. Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells.
Chen S; Qu X; Wan P; Li QW; Wang Z; Guo F; Bai L; Hu Z; Tan W; Li J
Am J Chin Med; 2013; 41(3):665-82. PubMed ID: 23711148
[TBL] [Abstract][Full Text] [Related]
11. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
12. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.
Chen YN; Chen JC; Yin SC; Wang GS; Tsauer W; Hsu SF; Hsu SL
Int J Cancer; 2002 Jul; 100(2):158-65. PubMed ID: 12115564
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
[TBL] [Abstract][Full Text] [Related]
14. N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production.
Chang MC; Wu JY; Liao HF; Chen YJ; Kuo CD
Anticancer Drugs; 2015 Nov; 26(10):1034-42. PubMed ID: 26288134
[TBL] [Abstract][Full Text] [Related]
15. Effects of a prospective antitumor agent, 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane diperchlorate, on cultured mammalian cells.
Traganos F; Darzynkiewicz Z; Bueti C; Melamed MR
Cancer Invest; 1984; 2(1):1-13. PubMed ID: 6584191
[TBL] [Abstract][Full Text] [Related]
16. Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.
Li M; Xu X; Lu F; Guo S
Drug Deliv; 2014 Jun; 21(4):293-301. PubMed ID: 24156408
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
18. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization.
Lu S; Gao Y; Huang X; Wang X
Int J Biol Sci; 2014; 10(4):415-25. PubMed ID: 24719559
[TBL] [Abstract][Full Text] [Related]
19. Elliptinium, norcantharidin and tetrachlordecaoxide in combined chemo-immunotherapy prolong the survival of Friend-virus-infected mice.
Liu XH; Blazsek I; Breard J; Comisso M; Mathe G; Misset JL
Drugs Exp Clin Res; 1991; 17(9):419-26. PubMed ID: 1822434
[TBL] [Abstract][Full Text] [Related]
20. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
